{
  "@context": "http://id.who.int/icd/contexts/contextForLinearizationEntity.json",
  "@id": "http://id.who.int/icd/release/11/2024-01/mms/3100933",
  "parent": [
    "http://id.who.int/icd/release/11/2024-01/mms/1099536224"
  ],
  "browserUrl": "https://icd.who.int/browse/2024-01/mms/en#3100933",
  "code": "HA40.2",
  "source": "http://id.who.int/icd/entity/3100933",
  "classKind": "category",
  "title": {
    "@language": "en",
    "@value": "Aetiological considerations associated with use of psychoactive substance or medication"
  },
  "definition": {
    "@language": "en",
    "@value": "This category should be assigned when there is evidence that the direct physiological effects of a psychoactive substance or medication are an important contributing factor to the Sexual Dysfunction or Sexual Pain Disorder. Examples include selective serotonin reuptake inhibitors, histamine-2 receptor antagonists (e.g., cimetidine), alcohol, opioids, and amphetamines. If the diagnostic requirements for a Disorder Due to Substance Use are met, the appropriate Disorder Due to Substance Use diagnosis should also be assigned."
  },
  "indexTerm": [
    {
      "label": {
        "@language": "en",
        "@value": "Aetiological considerations associated with use of psychoactive substance or medication"
      }
    }
  ]
}